Masiá M - Search Results

1

Daily tenofovir disoproxil fumarate/emtricitabine and hydroxychloroquine for pre-exposure prophylaxis of COVID-19: a double-blind placebo-controlled randomized trial in healthcare workers.

Polo R, García-Albéniz X, Terán C, Morales M, Rial-Crestelo D, Garcinuño MA, García Del Toro M, Hita C, Gómez-Sirvent JL, Buzón L, Díaz de Santiago A, Arellano JP, Sanz J, Bachiller P, Alfaro EM, Díaz-Brito V, Masiá M, Hernández-Torres A, Guerra JM, Santos J, Arazo P, Muñoz L, Arribas JR, Martínez de Salazar P, Moreno S, Hernán MA, Del Amo J; EPICOS. Polo R, et al. Among authors: masia m. Clin Microbiol Infect. 2023 Jan;29(1):85-93. doi: 10.1016/j.cmi.2022.07.006. Epub 2022 Aug 5. Clin Microbiol Infect. 2023. PMID: 35940567 Free PMC article. Clinical Trial.

2

Decrease in serial prevalence of coinfection with hepatitis C virus among HIV-infected patients in Spain, 1997-2006.

Pérez Cachafeiro S, Del Amo J, Iribarren JA, Salavert Lleti M, Gutiérrez F, Moreno A, Labarga P, Pineda JA, Vidal F, Berenguer J, Moreno S; Cohorts of the Spanish AIDS Research Network (CoRIS and CoRIS-MD). Pérez Cachafeiro S, et al. Clin Infect Dis. 2009 May 15;48(10):1467-70. doi: 10.1086/598333. Clin Infect Dis. 2009. PMID: 19368502

3

A pilot randomized trial comparing an intensive versus a standard intervention in stable HIV-infected patients with moderate-high cardiovascular risk.

Masiá M, Bernal E, Padilla S, García N, Escribano JC, Martínez E, Gutiérrez F. Masiá M, et al. J Antimicrob Chemother. 2009 Sep;64(3):589-98. doi: 10.1093/jac/dkp250. Epub 2009 Jul 22. J Antimicrob Chemother. 2009. PMID: 19625372 Clinical Trial.

4

Most HIV type 1 non-B infections in the Spanish cohort of antiretroviral treatment-naïve HIV-infected patients (CoRIS) are due to recombinant viruses.

Yebra G, de Mulder M, Martín L, Rodríguez C, Labarga P, Viciana I, Berenguer J, Alemán MR, Pineda JA, García F, Holguín A; Cohort of the Spanish AIDS Research Network (CoRIS). Yebra G, et al. J Clin Microbiol. 2012 Feb;50(2):407-13. doi: 10.1128/JCM.05798-11. Epub 2011 Dec 7. J Clin Microbiol. 2012. PMID: 22162552 Free PMC article.

5

Incidence and risk factors of AIDS-defining cancers in a cohort of HIV-positive adults: Importance of the definition of incident cases.

Suárez-García I, Jarrín I, Iribarren JA, López-Cortés LF, Lacruz-Rodrigo J, Masiá M, Gómez-Sirvent JL, Hernández-Quero J, Vidal F, Alejos-Ferreras B, Moreno S, Del Amo J. Suárez-García I, et al. Among authors: masia m. Enferm Infecc Microbiol Clin. 2013 May;31(5):304-12. doi: 10.1016/j.eimc.2012.03.009. Epub 2012 May 18. Enferm Infecc Microbiol Clin. 2013. PMID: 22608566

6

Endothelial function in HIV-infected patients switching from a boosted protease inhibitor-based regimen to raltegravir: a substudy of the SPIRAL study.

Masiá M, Martínez E, Padilla S, Gatell JM, Gutiérrez F. Masiá M, et al. J Antimicrob Chemother. 2013 Feb;68(2):409-13. doi: 10.1093/jac/dks412. Epub 2012 Oct 17. J Antimicrob Chemother. 2013. PMID: 23075691 Clinical Trial.

7

What drives the number of high-risk human papillomavirus types in the anal canal in HIV-positive men who have sex with men?

del Amo J, González C, Geskus RB, Torres M, Del Romero J, Viciana P, Masiá M, Blanco JR, Hernández-Novoa B, Ortiz M; CoRIS-HPV Study Group. del Amo J, et al. Among authors: masia m. J Infect Dis. 2013 Apr 15;207(8):1235-41. doi: 10.1093/infdis/jit028. Epub 2013 Jan 16. J Infect Dis. 2013. PMID: 23325914

8

Long-term effects of an intensive intervention in HIV-infected patients with moderate-high atherosclerotic cardiovascular risk.

Masiá M, Bernal E, Robledano C, Padilla S, López N, Martínez E, Gutiérrez F. Masiá M, et al. J Antimicrob Chemother. 2014 Nov;69(11):3051-6. doi: 10.1093/jac/dku269. Epub 2014 Jul 18. J Antimicrob Chemother. 2014. PMID: 25038306

9

Shorter telomere length predicts poorer immunological recovery in virologically suppressed HIV-1-infected patients treated with combined antiretroviral therapy.

Blanco JR, Jarrin I, Martinez A, Siles E, Larrayoz IM, Cañuelo A, Gutierrez F, Gonzalez-Garcia J, Vidal F, Moreno S; CoRIS-Biobanco. Blanco JR, et al. J Acquir Immune Defic Syndr. 2015 Jan 1;68(1):21-9. doi: 10.1097/QAI.0000000000000398. J Acquir Immune Defic Syndr. 2015. PMID: 25321176

10

Safety, efficacy and indications of prescription of maraviroc in clinical practice: Factors associated with clinical outcomes.

Llibre JM, Rivero A, Rojas JF, Garcia Del Toro M, Herrero C, Arroyo D, Pineda JA, Pasquau J, Masiá M, Crespo M, Blanco JR, Moreno S. Llibre JM, et al. Among authors: masia m. Antiviral Res. 2015 Aug;120:79-84. doi: 10.1016/j.antiviral.2015.05.001. Epub 2015 May 12. Antiviral Res. 2015. PMID: 25977241

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

380 results

Search Page